Biologically Focused Therapy of Treatment-Refractory MDS Patients

Not Recruiting

Trial ID: NCT05245032


This non interventional study examines the feasibility of using patient specific therapeutic screening method, ex vivo to enhance current treatment recommendations in a clinically feasible time frame of 30 days.

Official Title

Biologically Focused Therapy of Treatment Refractory MDS Patients

Stanford Investigator(s)

Peter Greenberg
Peter Greenberg

Professor of Medicine (Hematology), Emeritus


Inclusion Criteria:

   - Provide informed consent;

   - Myelodysplastic syndrome as defined by WHO classification (see Appendix 2), or MDS/MPN
   with >= 5% blasts in the bone marrow or peripheral blood, including chronic
   myelomonocytic leukemia (CMML) 1 and 2 by WHO classification

   - Relapsed/refractory disease, defined as failed or are ineligible for hypomethylating
   agent therapy

   - Cytogenetics reported

Exclusion Criteria:

   - Hypoplastic MDS

   - Patients without adequate marrow samples for ex vivo analysis

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Jack Taw

New Trial Alerts

Receive email alerts when trials open to patients.